title: Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris.
abstract: Propionibacterium acnes is a key pathogen involved in the progression of inflammation in acne vulgaris. We examined whether vaccination against P. acnes suppressed P. acnes-induced skin inflammation. Inactivation of P. acnes with heat was employed to create a P. acnes-based vaccine. Intranasal immunization in mice with this inactivated vaccine provoked specific antibodies against P. acnes. Most notably, immunization with inactivated vaccines generated in vivo protective immunity against P. acnes challenge and facilitated the resolution of ear inflammation in mice. In addition, antibodies elicited by inactivated vaccines effectively neutralized the cytotoxicity of P. acnes and attenuated the production of proinflammatory cytokine IL-8 in human sebocyte SZ95 cells. Intranasal immunization using heat-inactivated P. acnes-based vaccines provided a simple modality to develop acne vaccines. These observations highlight the concept that development of vaccines targeting microbial products may represent an alternative strategy to conventional antibiotic therapy.
authors.affiliation: Division of Dermatology, Department of Medicine, University of California, San Diego, California 92161, USA.
authors.forename: Teruaki
authors.initials: T
authors.lastname: Nakatsuji
authors.forename: Yu-Tsueng
authors.initials: YT
authors.lastname: Liu
authors.forename: Cheng-Po
authors.initials: CP
authors.lastname: Huang
authors.forename: Christos C
authors.initials: CC
authors.lastname: Zoubouis
authors.forename: Richard L
authors.initials: RL
authors.lastname: Gallo
authors.forename: Chun-Ming
authors.initials: CM
authors.lastname: Huang
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology* / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002460:Cell Line; D003872:Dermatitis / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D051379:Mice; D008813:Mice, Inbred ICR; D011425:Propionibacterium acnes / Q000276:immunology*; D012627:Sebaceous Glands / Q000378:metabolism* / Q000473:pathology; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D016209:Interleukin-8; D015164:Vaccines, Inactivated